Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples